Congress of Clinical Rheumatology West (CCR West), 2024

Bimekizumab Efficacy Across Subgroups of Patients With Moderate to Severe Plaque Psoriasis: Pooled Analysis From up to 3 Years of Treatment in 5 Phase 3/3b Clinical Trials

Bimekizumab-Treated Patients With Psoriatic Arthritis Showed Sustained Improvements in HRQoL and Work Productivity Up To 2 Years